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Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a rare
monogenic primary immunodeficiency (PID) due to mutations of FOXP3, a key transcrip-
tion factor for naturally occurring (n) regulatoryT (Treg) cells.The dysfunction ofTreg cells is
the main pathogenic event leading to the multi-organ autoimmunity that characterizes IPEX
syndrome, a paradigm of genetically determined PID with autoimmunity. IPEX has a severe
early onset and can become rapidly fatal within the first year of life regardless of the type
and site of the mutation. The initial presenting symptoms are severe enteritis and/or type-
1 diabetes mellitus, alone or in combination with eczema and elevated serum IgE. Other
autoimmune symptoms, such as hypothyroidism, cytopenia, hepatitis, nephropathy, arthri-
tis, and alopecia can develop in patients who survive the initial acute phase. The current
therapeutic options for IPEX patients are limited. Supportive and replacement therapies
combined with pharmacological immunosuppression are required to control symptoms at
onset. However, these procedures can allow only a reduction of the clinical manifesta-
tions without a permanent control of the disease. The only known effective cure for IPEX
syndrome is hematopoietic stem cell transplantation, but it is always limited by the avail-
ability of a suitable donor and the lack of specific guidelines for bone marrow transplant
in the context of this disease. This review aims to summarize the clinical histories and
genomic mutations of the IPEX patients described in the literature to date. We will focus
on the clinical and immunological features that allow differential diagnosis of IPEX syn-
drome and distinguish it from other PID with autoimmunity. The efficacy of the current
therapies will be reviewed, and possible innovative approaches, based on the latest high-
lights of the pathogenesis to treat this severe primary autoimmune disease of childhood,
will be discussed.
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INTRODUCTION
Immune dysregulation, polyendocrinopathy, enteropathy, X-
linked (IPEX) syndrome is a rare monogenic primary immun-
odeficiency (PID), characterized by multi-organ autoimmunity. It
is caused by mutations in the transcription factor forkhead box p3
(FOXP3), the master gene of T regulatory (Treg) cells. The dis-
ease shows an X-linked hereditary pattern: only males are affected,
whereas the carrier mothers are healthy.
Although IPEX syndrome is a rare disease, the recent increase
in the number of patients referred for diagnosis suggests that
the occurrence of the disease has been underestimated so far. At
present, 63 FOXP3 mutations have been published, for an overall
number of 136 patients described, and of these about half have
been diagnosed in the last 3 years. This also indicates that the
awareness of the disease has been growing with a better under-
standing of the role of FOXP3 and Treg cells in maintaining
peripheral tolerance.
Overall, the analysis of cases reported so far (Table 1) confirms
the relevance of the three main clinical manifestations and their
early onset while highlighting the occurrence of unusual symp-
toms. The genetic analysis is always required for accurate diagnosis,
although other tests such as tissue biopsy and/or autoantibody
detection are important, as complementary tools, in the diagnostic
process and follow-up.
IPEX syndrome can be fatal in early infancy if not recognized,
therefore a timely diagnosis is essential to start appropriate treat-
ment. Treating IPEX patients poses a threefold challenge: autoim-
munity, infections supported by the autoimmune damage, and the
severity of the overall picture. Both novel and existing therapeutic
approaches will be discussed with an emphasis on the central role
of Treg cell impairment in the pathogenesis of IPEX syndrome.
GENETICS OF IPEX SYNDROME
Immune dysregulation, polyendocrinopathy, enteropathy, X-
linked syndrome was described for the first time in 1982 in a large
family with 19 affected males across five generations,as an X-linked
syndrome with diarrhea that was lethal in most male infants by
the first months or years of life (Powell et al., 1982). Only 20 years
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later, in two unrelated kindred with IPEX phenotype, Chatila et al.
(2000) identified mutations in JM2 (later called FOXP3) in the
centromeric region of the X chromosome (Xq11.3-q13.3). Shortly
after, Bennett et al. (2001b) and Wildin et al. (2001) confirmed
that IPEX syndrome is the human equivalent of the scurfy mouse,
the natural mouse model of the disease, and identified mutations
in the FOXP3 gene in additional IPEX patients. Of note, in the
first family described in 1982, the disease mapped to the pericen-
tromeric region of the X chromosome (Bennett et al., 2000), but
no identifiable mutation on FOXP3 was found, so that it was sus-
pected to have a non-coding mutation that affects transcriptional
regulation or RNA splicing (Bennett et al., 2001b).
The highly conserved FOXP3 gene is composed of 12 exons
encoding a protein of 431 amino acids in humans. Among
the 63 mutations reported thus far (Figure 1), the majority of
them (27/63) alter the C-terminal forkhead (FKH) DNA-binding
domain of the protein, while the remaining of the mutations
occur outside the FKH domain. The latter include mutations
affecting the N-terminal proline-rich (PRR) domain (14/63), the
leucine-zipper (LZ) domain (5/63), the LZ-FKH loop (9/63), the
region upstream the initial ATG (3/63), and the C-terminal (3/63;
Figure 1).
Moreover, mutations of the polyadenylation site of the gene
(2/63) have been described, which lead to the expression of an
unstable FOXP3 mRNA and usually result in severe, early onset
disease (Bennett et al., 2001a; Dorsey et al., 2009; Tsuda et al.,
2010; Passerini et al., 2011b). Patients with mutations that abro-
gate expression of functional FOXP3 protein (i.e., missense or
frameshift mutations or splicing defects resulting in a premature
stop codon) tend to have severe presentation as well (Gavin et al.,
2006; Gambineri et al., 2008; Burroughs et al., 2010; An et al.,
2011). Nonetheless, the severity of the disease is not always depen-
dent on the absence of protein expression. The majority of affected
individuals have missense mutations (usually point mutations)
resulting in a normal or reduced level of expression of mutant
protein. Such mutations lead to an impaired transcriptional regu-
latory activity by altering the binding sites to DNA, the interaction
with other molecules (e.g., NFAT,AP1, RORα), or the dimerization
of FOXP3 (Figure 1).
Independently from the type or site of the FOXP3 mutation,
all patients described but five (Ferguson et al., 2000; Fuchizawa
et al., 2007; Rubio-Cabezas et al., 2009; Scaillon et al., 2009; Tsuda
et al., 2010; Otsubo et al., 2011) developed gastrointestinal symp-
toms (mainly diarrhea).The exact nature of genotype-phenotype
correlation has been difficult to pinpoint, especially considering
the age at onset and the disease outcome. For example, in 13
patients presenting with the same mutation (c.1150G>A), the
onset ranged from birth to 7 months (Table 1). In addition the
outcome was influenced by other factors such as timing of the ther-
apeutic intervention, concomitant infections, and each individual
patient’s response to therapy.
The histopathological lesions also differ among the patients
carrying the same mutation, further suggesting that the genotype
does not strictly correlate with phenotypical changes of the tar-
get organs (Patey-Mariaud de Serre et al., 2009). This inconsistent
correlation between genotype and phenotype may reflect the com-
plex intracellular interactions of FOXP3 (Allan et al., 2005) and
also strongly suggests the role of environmental or epigenetic fac-
tors that might participate in determining the clinical picture and
outcome (Gambineri et al., 2008).
CLINICAL MANIFESTATIONS
Most IPEX patients are born at term after an uneventful preg-
nancy from unrelated parents. A careful family history may reveal
the presence of male subjects in the maternal lineage with similar
clinical phenotype, early death, or multiple spontaneous abor-
tions. Notably, these patients may have other affected brothers,
but females belonging to the same lineage are usually healthy.
At birth, they may have a normal weight and length without
pathological findings. The onset of IPEX syndrome usually occurs
FIGURE 1 | Schematic representation of the FOXP3 gene reporting all the
mutations published so far. Annotations refer to both coding sequence and
protein, when applicable (www.ncbi.nlm.nih.gov/CCDS, accession number
CCDS14323.1). *c543C>T is a polymorphism. E, exon; Color code: orange,
N-terminal domain; green, zinc finger domain; blue, leucin-zipper domain; red,
forkhead domain.
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in males within their first months of life, but in some cases even
after few days or weeks, and can be rapidly fatal if not diagnosed
and treated. The most severe cases are characterized by the early
onset of a triad of clinical manifestations: intractable diarrhea,
type-1 diabetes mellitus (T1DM), and eczema.
Autoimmune enteropathy is a hallmark of IPEX syndrome.
Patients present with neonatal, watery, and sometimes mucoid or
bloody acute diarrhea. This acute severe enteropathy often begins
in the first days of life or during breast-feeding, thus showing to
be independent from cow milk or gluten introduction in the diet.
However, it could be worsen by switching from breast-feeding to
regular formula. It typically persists despite dietary exclusions and
bowel rest. Since it results in severe malabsorption and significant
failure to thrive, parenteral nutrition is often required. In addition
to diarrhea, other gastrointestinal manifestations can present, such
as vomiting (Ferguson et al., 2000; Hashimura et al., 2009; Har-
buz et al., 2010; Otsubo et al., 2011), gastritis (Nieves et al., 2004;
Gambineri et al., 2008; Scaillon et al., 2009), ileus (Levy-Lahad and
Wildin, 2001), and colitis (Lucas et al., 2007; Otsubo et al., 2011;
Table 1).
Type-1 diabetes mellitus can precede or follow enteritis. T1DM
is present in the majority of patients including newborns, and
is usually difficult to control (Peake et al., 1996; Baud et al.,
2001; Gambineri et al., 2008). There have been rare cases (6/136)
presenting with diabetes mellitus without auto-antibodies (Rubio-
Cabezas et al., 2009; Scaillon et al., 2009). Imaging studies or
autopsy and histological examination often reveal destruction of
the pancreas and intense lymphocytic infiltrate, suggesting that
an immune mediated damage of this organ may have a role in
the pathogenesis (Wildin et al., 2002; Costa-Carvalho et al., 2008;
Rubio-Cabezas et al., 2009).
Cutaneous manifestations appear in the first months of life.
Similar to diarrhea and diabetes, cutaneous manifestations are
very common (95/136) and can be the first sign of the disease
(Table 1).
Dermatitis can be eczematiform (mainly atopic dermatitis)
(Wildin et al., 2002; Owen et al., 2003; Ruemmele et al., 2008),
ichthyosiform (Baud et al., 2001; Rao et al., 2007), psoriasiform
(Nieves et al., 2004; De Benedetti et al., 2006), or any combina-
tion of the above (e.g., atopic dermatitis and psoriasis coexisting
on different areas of the skin) (Halabi-Tawil et al., 2009). Skin
involvement is severe and diffuse, characterized by erythematous
exudative plaques that could evolve into more lichenfied plaques
(Halabi-Tawil et al., 2009). Pruritus can be a major complain
in these patients since it is intense and difficult to control with
anti-histamine drugs. Cutaneous lesions often show resistance to
classic treatments such as topical steroids or tacrolimus and can
be complicated by bacterial infections (most commonly Staphy-
lococcus aureus and epidermidis) with potential development of
sepsis (Halabi-Tawil et al., 2009). Other manifestations affecting
the integumentary system include: painful and fissurary cheilitis
(Halabi-Tawil et al., 2009), onychodystrophy (Halabi-Tawil et al.,
2009), and alopecia (Nieves et al., 2004; Moudgil et al., 2007;
Gambineri et al., 2008).
Two patients presented with severe allergies to food or other
allergens causing asthma, skin rashes, and gastrointestinal symp-
toms in the absence of endocrinopathies. These patients were
initially diagnosed and treated as severely allergic individuals
(Torgerson et al., 2007). Given this, severe allergic conditions in
association with other autoimmune symptoms should raise the
suspicion of IPEX syndrome.
The clinical picture can be complicated by the presence of other
autoimmune symptoms (Table 1): thyroiditis (27/136) with either
hyperthyroidism or, more commonly, hypothyroidism (Kobayashi
et al., 2001;Wildin et al., 2001, 2002; Nieves et al., 2004; Myers et al.,
2006; Moudgil et al., 2007; Costa-Carvalho et al., 2008; Gambineri
et al., 2008; Halabi-Tawil et al., 2009; Rubio-Cabezas et al., 2009;
Wang et al., 2010; Otsubo et al., 2011) cytopenias (42/136) such
as hemolytic anemia, thrombocytopenia, and neutropenia, and
hepatitis (8/136) that may be autoimmune with positive auto-
antibodies (Table 1). Renal disease can be related either to autoim-
munity or to prolonged administration of nephrotoxic drugs. They
are generally described as tubulonephropathy (Kobayashi et al.,
2001; Otsubo et al., 2011) and nephrotic syndrome (Gambineri
et al., 2008; Rubio-Cabezas et al., 2009; An et al., 2011; Otsubo
et al., 2011), although interstitial nephritis (Bindl et al., 2005;
Patey-Mariaud de Serre et al., 2009; Moes et al., 2010) and mem-
branous glomerulonephritis (Moudgil et al., 2007; Halabi-Tawil
et al., 2009; Burroughs et al., 2010; Bae et al., 2011) have also
been found in some patients’ histopathological examinations. A
rare manifestation associated with the milder forms of IPEX with
delayed diagnosis is arthritis involving one or more joints (Wildin
et al., 2002; De Benedetti et al., 2006). Splenomegaly and lym-
phadenopathy may progress as a result of an ongoing autoimmune
lymphoproliferation, as evidenced by the extensive lymphocytic
infiltrates in secondary lymphoid organs found in several patients
during autopsy (Wildin et al., 2002; Ochs and Torgerson, 2007;
Costa-Carvalho et al., 2008). Despite multiple and early autoim-
mune manifestations typical of IPEX syndrome, it is important to
underline that their number may increase with age. IPEX patients’
presentation typically begins early with some of these autoimmune
symptoms, and progresses with new manifestations over years.
The clinical spectrum can be worsened by infections, although
they are less frequent than the more prominent signs described
above. The onset of IPEX syndrome is often associated with infec-
tions, however a clear causative role of pathogens in the onset of
autoimmunity has not been demonstrated and infections can often
be the consequence of multiple immunosuppressive (IS) therapy
and poor clinical conditions.
The most frequent infections are pneumonia, airway infections,
gastrointestinal, and skin super-infections that may lead to life-
threatening sepsis from Enterococcus spp. and Staphylococcus spp.
(Halabi-Tawil et al., 2009). Other common pathogens are Clostrid-
ium difficile, Candida albicans, Pneumocystis jiroveci, CMV, and
EBV.
LABORATORY FINDINGS
Laboratory tests can be normal at onset. There are no specific diag-
nostic findings in IPEX syndrome although the laboratory abnor-
malities consistent with T1DM and severe enteropathy are com-
mon. Moreover, other alterations may suggest ongoing autoim-
mune manifestations in other target organs, such as hypothy-
roidism, cytopenias, hepatitis, or nephropathy. Markedly elevated
IgE levels and eosinophil counts are observed in the majority
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of patients as an early hallmark of the disease (Table 1). Serum
IgA, IgG, and IgM levels are generally normal or low due to the
protein-losing enteropathy.
Patients in the acute phase of the disease, prior to IS therapy,
can have normal or elevated white blood cell counts. Leukocytosis,
if present, is due to an increase in lymphocytes but the percent-
age of the different lymphocyte subpopulations (CD3, CD4, CD8,
CD16, CD19) remains unchanged despite immune dysregulation.
The CD4/CD8 ratio is maintained or increased and the T cell
repertoire is polyclonal. The percentages of naive and memory T
cells are mostly comparable to their age-matched controls. The
CD4+CD25+FOXP3+ Treg cells are present (Gavin et al., 2006;
Gambineri et al., 2008), but FOXP3 expression can be reduced if
FOXP3 mutation prevents the expression of the protein (Bacchetta
et al., 2006) or if the patient is exposed to IS therapy (Gam-
bineri et al., 2008). In addition, in vitro proliferative responses
to mitogens are normal unless the patient is treated with IS drugs
(Bacchetta et al., 2006). The in vitro cytokine production shows a
decrease in Th1 cytokines and an increase in Th2 (Chatila et al.,
2000; Nieves et al., 2004; Bacchetta et al., 2006). The karyotype is
normal.
A variety of auto-antibodies are detected in most patients and
their presence usually correlates with signs of pathology in the tar-
get organs, but their production may also be a sign of immune
dysregulation without an obvious pathological linkage (Tsuda
et al., 2010).
There is increasing evidence that anti-enterocyte antibodies
are characteristic of IPEX patients, although not all patients
have been tested because the assay is not widely accessible. The
autoimmune enteropathy-related 75 kDa antigen (AIE-75), pre-
dominantly expressed in brush border of the small intestine and
proximal tubules of the kidney, has been identified as a specific tar-
get of the auto-antibodies present in IPEX patients sera (Kobayashi
et al., 1998, 1999, 2011; Gambineri et al., 2003; Patey-Mariaud de
Serre et al., 2009; Moes et al., 2010).
In addition, a recent study of Kobayashi et al. identified villin,
a 95-kDa actin-binding protein, as another brush border anti-
gen aberrantly targeted in IPEX syndrome. Like AIE-75, villin
is also expressed both in the microvilli of the small intestine
and in the proximal renal tubules. In this study, five out of five
IPEX patients showed anti-AIE-75 antibodies and four out of five
displayed anti-villin antibodies. None of the control sera from
healthy subjects or patients affected by non-IPEX pathologies (e.g.,
autoimmune enteropathies of different origin, enterocolitis, and
colon cancer) were positive for anti-AIE-75 antibodies and only a
few were weakly positive for anti-villin antibodies. High levels of
anti-villin auto-antibodies have been found only in children with
IPEX syndrome (Kobayashi et al., 2011). These findings confirm
the specificity of both anti-AIE-75 and anti-villin antibodies for
IPEX syndrome. Their link to the tissue damage, the correlation
to the progression of the disease, and their predictive value have
to be clarified.
Early presence of detectable auto-antibodies against insulin,
pancreatic islet cells, or anti-glutamate decarboxylase correlates
with occurrence of neonatal T1DM. Moreover, anti-thyroglobulin
and anti-microsome peroxidase antibodies are detected in
autoimmune thyroiditis even in the absence of functional
impairment; Coombs antibodies, anti-platelets antibodies, and
anti-neutrophils antibodies are often present in autoimmune
cytopenias; anti-smooth muscle (ASMA) and anti-liver-kidney-
muscle (anti-LKM) antibodies are positive in autoimmune hepati-
tis. Recently, Huter et al. (2010) reported that sera from IPEX
patients react against keratins, especially keratin 14, suggesting
this molecule as a target for autoreactive lymphocytes in the skin
of IPEX patients.
Although there is no pathognomonic finding specific to IPEX,
biopsies of the affected organs can help in excluding other etiolo-
gies. Main histological findings in the gastrointestinal tracts are
total or subtotal villous atrophy with mucosal lymphocytic and
eosinophil infiltration, but they are not specific for the disease. In
a recent work,Patey-Mariaud de Serre and colleagues described the
intestinal morphological changes of twelve IPEX patients (Patey-
Mariaud de Serre et al., 2009). Three different kinds of lesions
were found in the gastrointestinal tract: (1) the graft-versus-host
disease-like pattern was the most frequent form observed; (2) the
celiac disease-like pattern, found in two patients; (3) depletion of
the intestinal goblet cells along with the presence of anti-goblet
cell auto-antibodies, reported in one child. Hence, one of these
histopathological patterns in the proper clinical context and an
association with circulating anti-AIE-75 auto-antibodies would
suggest the diagnosis of IPEX syndrome.
In addition, one case reported the autoimmune destruction
of pancreatic exocrine cells contributing to the diarrheal disease
(Heltzer et al., 2007).
The histopathological changes at the skin biopsies are usually
non-specific for IPEX syndrome since there is a wide range of
possible dermatological pictures. The clinical and histopathologi-
cal features of skin pathology of 10 IPEX patients were described
by Halabi-Tawil et al. (2009). Either subacute /chronic spongiotic
dermatitis or psoriasiform changes, also consistent with a chronic
lichenified eczema, have been shown. One out of the four biopsies
showed a slight perivascular lymphocytic infiltrate in the upper
dermis, while the others showed a moderate to intense superfi-
cial dermal infiltrate with the simultaneous presence of eosinophil
and lymphocyte infiltrates. Although the majority of skin alter-
ations were compatible with atopic or psoriasiform dermatitis,
IPEX patients may present with uncommon allergic (Nieves et al.,
2004), autoimmune (Ferguson et al., 2000; McGinness et al., 2006),
or infectious (McLucas et al., 2007) dermatological complications.
DIFFERENTIAL DIAGNOSIS
A neonate presenting a single severe manifestation of IPEX syn-
drome such as enteropathy, diabetes, or newborn erythroderma
may pose a diagnostic challenge for the physician. For each of
them, the suspicion of IPEX syndrome should be raised once other
more common diseases have been excluded.
In a neonate presenting with isolated diarrhea, an autoimmune
pathogenesis of the enteropathy is a rare event. Table 2 provides
a summary of the possible causes of enteropathy in newborns
and infants. IPEX enteropathy, like other diarrheal diseases, may
have either an aggressive or insidious onset. When the onset of
the diarrhea is acute, microbial origins need to be excluded first.
When the diarrhea persists, a wide range of differential diagnosis
has to be considered (Murch, 2001). The most common cause is
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Table 2 | Differential diagnosis of early onset persistent diarrhea.
Infectious and post-enteritis diarrhea
FOOD-SENSITIVE ENTEROPATHY OR ENTEROCOLITIS
Cow’s milk sensitive enteropathy (most frequent)
Celiac disease
Non-celiac gluten sensitivity
Food protein induced enterocolitis
Eosinophilic gastroenteropathy
ANATOMICAL DEFECTS AND DYSMOTILITY DISORDERS
Hirschsprung disease
Intestinal lymphangiectasia
Short bowel syndrome (post surgery)
Stagnant loop syndrome (post surgery)
Chronic intestinal pseudo-obstruction
TRANSPORT DEFECTS
Chloride-bicarbonate exchanger defect (chloride-losing diarrhea)
Sodium hydrogen exchanger (congenital sodium diarrhea)
Ileal bile acid receptor defect
Sodium-glucose cotransporter defect (glucose-galactose malabsorption)
Abetalipoproteinemia
Hypolipoproteinemia
Acrodermatitis enteropathica (zinc deficiency)
ENZYMATIC DEFECTS
Enterokinase deficiency








IMMUNODEFICIENCIES (USUALLY UNMASKED BY A PATHOGEN)
Severe combined immunodeficiency (SCID)
Thymic hypoplasia
Class II major histocompatibility (MHCII) deficiency
CD40 ligand deficiency
Neutrophilic specific granule defect
Acquired immunodeficiency syndrome (AIDS)





food-sensitive enteropathy, so appropriate exclusion diets should
be initiated for an adequate period. Anatomical abnormalities
such as malrotation and pseudo-obstruction may cause bacterial
overgrowth with chronic diarrhea and malabsorption. If chronic
diarrhea is associated to protein-losing enteropathy, lymphangec-
tasia should also be considered. Transport or enzyme disorders
induce selective malabsorption of glucose-galactose, lipids, fat-
soluble vitamins, amino acids, electrolytes, and zinc (Murch, 2001,
2006). In some of these cases,diarrhea would be abrogated by with-
drawing oral feeding. Moreover, malabsorption could be in some
cases related to pancreatic disease rather than to an intestinal trans-
port or enzymatic alteration. Nevertheless, the intestinal biopsies
in both cases show a normal architecture with intact villous-
crypt axis, unlike in IPEX. On the contrary, primary epithelial
enteropathies, such as microvillous inclusion disease and tufting
enteropathy, are characterized by blunting villi at the intestinal
biopsy and usually appear in the first days after birth. They should
be excluded if diarrhea is prolonged and continues during total
parenteral nutrition (Sherman et al., 2004). Immunodeficiencies,
such as severe combined immunodeficiency (SCID) or interme-
diate forms of combined immunodeficiency (CID), may present
first with gastrointestinal symptoms, often fatal in early childhood
if untreated (Geha et al., 2007). In the latter cases, diarrhea may
be due to a prolonged impairment to clear enteric pathogens or
to a primary concomitant autoimmunity. Even metabolic diseases
or endocrinopathies could manifest with chronic diarrhea. Fur-
ther metabolic and hormonal assessment should be considered
in such cases. Autoimmune enteropathy is usually a diagnosis of
exclusion. Once the aforementioned diseases have been excluded
by appropriate clinical or laboratory evaluations, the presence of
the following clinical and histological findings indicative of the
autoimmune pathogenesis, should be considered: an unrespon-
siveness to dietary restriction and total parenteral nutrition, an
association with other autoimmune conditions (Unsworth and
Walker-Smith, 1985), small intestinal villous atrophy with hyper-
plastic crypt, mononuclear cells infiltrate within the intestinal
mucosa (Murch, 1997). Autoimmune enteropathy can be also one
of the symptoms of complex forms of immune dysregulation, but
other clinical or laboratory features usually help to distinguish
them from IPEX syndrome (Table 4).
The onset of permanent diabetes mellitus in the neonatal age
is described as a rare event (Rubio-Cabezas et al., 2010). Although
autoimmune T1DM is diagnosed in over 95% of children present-
ing with diabetes after 6 months of age (Porter and Barrett, 2004),
alternative etiologies should be considered in newborns and young
infants presenting with diabetes before 6 months of age (Hatter-
sley et al., 2009). Most of these patients have a monogenic form
of disease, even if the responsible gene remains unknown in up to
40% of patients (Edghill et al., 2008). The main monogenic causes
of early onset diabetes are mutations in Kir6.2 gene (the inward
rectifier subunit of the ATP-sensitive potassium channel of the β
cells), in SUR1 gene (the regulatory subunit of the KATP channel
in pancreatic β cells) and in the preproinsulin gene. Mutations of
chromosome 6q24 and mutations of the insulin gene may also be
considered (Valamparampil et al., 2009; Greeley et al., 2010). The
presence of auto-antibodies specific for pancreatic antigens before
6 months of age should however pose the question of FOXP3
mutation (Greeley et al., 2010). A recent study reported that 4%
of male patients with permanent neonatal diabetes were found to
have FOXP3 mutations (Rubio-Cabezas et al., 2009). The diag-
nosis of IPEX becomes more obvious when diabetes is preceded
or followed by other symptoms related to immune dysregulation,
such as enteropathy and eczema.
Skin pathology is a common finding in infants diagnosed with
IPEX syndrome. The absence of other clinical signs may delay
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Table 3 | Differential diagnosis of erythroderma presenting in the
neonatal period.
INFECTIONS
Staphylococcal scalded skin syndrome (SSSS)
Congenital cutaneous candidiasis
IMMUNODEFICIENCY
Graft-versus-host disease (GvHD) with underlying SCID
Omenn’s syndrome
ICHTHYOSES
Non-syndromic ichthyoses (non-bollous ichthyoses, bollous ichthyoses)













the diagnosis, especially in neonates and infants (Nieves et al.,
2004). The presentation ranges from mild eczema to severe gen-
eralized erythroderma or other unusual skin manifestations with
poor response to steroids (Halabi-Tawil et al., 2009; Redding et al.,
2009). Focusing on the neonates and infants presenting erythro-
derma as single diffuse manifestation of IPEX syndrome at onset,
Table 3 summarizes the possible clinical pictures that should be
considered for differential diagnosis (Hoeger and Harper, 1998;
Fraitag and Bodemer, 2010). Erythroderma is an inflammatory
skin disorder affecting the majority of the body surface, with sub-
acute or chronic evolution accompanied by scaling skin. In the
neonatal period, it can also be the primary manifestation of several
conditions. Perinatal or neonatal infections such as Staphylococcal
scalded skin syndrome (SSSS) and congenital cutaneous candidi-
asis may result in diffuse skin involvement. Skin swab and/or skin
biopsy is usually diagnostic.
Immunodeficiencies may present with extended skin alter-
ations as a result of the immune aggression sustained by autoreac-
tive newborn’s lymphocytes (as in Omenn’s syndrome) or mater-
nal lymphocytes expanding after birth in the immunodeficient
host (graft-versus-host disease with underlying SCID). Immuno-
logical assessment confirms the diagnosis of PID in these cases
(Table 4). If ichthyoses is suspected, skin biopsy is diagnostic.
Metabolic disorders can be associated with erythroderma, but usu-
ally it is not the only complain and other systemic signs can support
the diagnosis. Ceftriaxone or Vancomycin, if recently adminis-
tered, should be stopped immediately to rule out drug-induced
skin reactions. Other common skin pathology of infancy, e.g.,
atopic eczema and psoriasis, may evolve into erythroderma, but
the early presentation, the persistency of the lesions, and the lim-
ited response to topical treatment may increase the suspicion of
IPEX syndrome. As recently pointed out by Leclerc-Mercier et al.
(2010),early skin biopsy has a central role in excluding the majority
of these pathological conditions.
The clinical characteristics that are common in PID with
autoimmunity and unique to IPEX are summarized in Table 4.
The differential diagnoses with primary immunodeficiencies asso-
ciated with immune dysregulation and subsequent autoimmune
phenomena, such as CD25 deficiency, STAT5b deficiency, Omenn’s
syndrome, Wiskott–Aldrich syndrome, Hyper IgE syndrome,
autoimmune lymphoproliferative syndrome, autoimmune poly-
endocrinopathy candidiasis ectodermal dystrophy, should always
be considered.
FOXP3 DYSFUNCTION AND DISEASE PATHOGENESIS
Forkhead box p3 is a transcription factor, master regulator for
the function of thymic-derived regulatory T (nTreg) cells (Wildin
et al., 2001; Fontenot et al., 2003; Bacchetta et al., 2007; Gambineri
et al., 2008). These cells are among the main subsets of CD4+ T
cells appointed to maintain peripheral self-tolerance.
CD4+CD25+FOXP3+ T cells can be present in normal per-
centage in the peripheral blood of the IPEX patients. This was
demonstrated not only by immunophenotype, but also by analy-
sis of the Treg-cell-specific-demethylated-region (TSDR; Passerini
et al., 2011b; Barzaghi et al., 2012), whose demethylation ensures
cell-specific stable expression of FOXP3 (Baron et al., 2007; Wiec-
zorek et al., 2009).Therefore, in IPEX patients FOXP3mut Treg
cells are physically present but functionally impaired, and this is
considered the primary direct cause of autoimmunity in IPEX
(Bacchetta et al., 2006; D’Hennezel et al., 2009; Moes et al., 2010).
In this respect, IPEX syndrome is the best example of monogenic
autoimmune disease due to Treg deficiency. However, autoimmu-
nity in other immunodeficiencies, such as ADA-SCID and WAS,
has been recently associated with altered function of Treg cells,
regardless of FOXP3 expression (Marangoni et al., 2007; Sauer
et al., 2012).
Despite the general consensus on the fact that FOXP3 is funda-
mental for acquisition and maintenance of suppressive function
by nTreg cells (Gavin et al., 2007; Wan and Flavell, 2007; Williams
and Rudensky, 2007), it is unclear how the different mutations
affect their function. Functional in vitro studies on Treg cells of
IPEX patients revealed that the degree of functional impairment of
the suppressive activity varies among the patients, with complete
abrogation of suppressive function in patients with null mutations
(Bacchetta et al., 2006). Similarly, mutations in the FKH DNA-
binding domain of FOXP3 that caused severe IPEX (p.R347H and
p.F373A) were only partially blocked in their ability to reprogram
conventional T cells into Treg cells (McMurchy et al., 2010). It may
therefore be hypothesized that some mutated forms of the pro-
tein retain residual protein activities, thus only partially impairing
FOXP3 functions. The molecular mechanisms of Treg-mediated
suppression remain controversial, hence our understanding of the
impact of different FOXP3 mutations on Treg cell function is
incomplete.
In addition to the well-accepted loss of suppressive function,
we recently described that FOXP3 mutations cause high insta-
bility of the Treg cell compartment, with a marked shift to the
Th17 cell phenotype of bona fide nTreg cells expressing a mutated
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form of FOXP3 (Passerini et al., 2011b). Indeed, the plasticity
between different CD4+ T cell subsets is a new and dynamic con-
cept, particularly pronounced between the Th17 and Treg cell
compartments (Lee et al., 2009), although the in vivo relevance
of such phenomenon is controversial (Zhou et al., 2009; Rubtsov
et al., 2010). Thus, in addition to the loss of suppressive function,
FOXP3 mutations are associated with inflammation-driven con-
version from a regulatory to an effector (i.e., IL-17-producing)
phenotype of mutated Treg cells, which may directly contribute to
the autoimmune damage in the target organs.
While the necessity of FOXP3 for suppressive function of Treg
cells is undisputed, it is unclear whether functional FOXP3 is
essential for thymic development of Treg cells in humans. Data
from murine models of FOXP3 deficiency indicate that FOXP3
is dispensable for thymic development of Treg cells, but rather
essential for their maintenance in the periphery, as demonstrated
in Foxp3gfpko female mice (Gavin et al., 2007) and in FILIG mice,
which display reduced Foxp3 expression in Treg cells (Wan and
Flavell, 2007). On the other hand, data from healthy carriers
of FOXP3 mutations and transplanted IPEX patients with low
peripheral donor chimerism clearly indicate that only Treg cells
expressing a wild type FOXP3 survive long term in the periphery,
although leave it unclear whether the selective advantage is already
active during thymic differentiation or occurs later on in life (Di
Nunzio et al., 2009; Seidel et al., 2009). Our recent observation that
bona fide Treg cells can be detected by TSDR demethylation analy-
sis in the peripheral blood of IPEX patients both at the onset of the
disease and several years after IS treatment, regardless of FOXP3
expression, demonstrates that functional FOXP3 is not necessary
for thymic differentiation of Treg cells in humans, as previously
demonstrated for murine Treg cells (Gavin et al., 2007), and that
FOXP3mut Treg cells can survive and be detected long term, in the
peripheral blood of patients with IPEX syndrome (Passerini et al.,
2011b; Barzaghi et al., 2012).
Evidences from studies on human and murine models show
that Type-1 regulatory T (Tr1) cells can contribute to suppress-
ing the development of autoimmunity in addition to nTreg cells
(Roncarolo et al., 2006; Sakaguchi, 2006). We recently demon-
strated that Tr1 cells can develop in IPEX patients regardless of
FOXP3 expression (Passerini et al., 2011a). This observation sug-
gests that FOXP3-independent immune regulation can potentially
contribute to controlling the disease, although Tr1 cells alone do
not seem adequate to suppress the initial acute phase of the dis-
ease. Thus, it is tempting to conclude that FOXP3 is not necessary
for function and development of adaptive Treg cells, the IL-10
producing Tr1 cells.
In humans, FOXP3 is also expressed transiently upon activa-
tion, in conventional Teff cells (Allan et al., 2007; Tran et al., 2007;
Passerini et al., 2008), in which a still unknown function has been
postulated (Ziegler, 2006; McMurchy et al., 2010). This implies
that FOXP3 mutations may also impinge on Teff cell function
and suggests that FOXP3-dependent Teff impaired function may
directly contribute to the pathogenic mechanism underlying the
disease. In support of this hypothesis are the data demonstrating
an impaired Th1 cytokine production from IPEX T cells, with rel-
ative increase of Th2 cytokines (Chatila et al., 2000; Nieves et al.,
2004; Bacchetta et al., 2006). In addition, we observed an increased
proportion of IL-17 producing cells in the patients’ PBMC, which
could be derived in part from converted Treg, as mentioned above,
or in part from Teff cells.
Overall, our current view of the pathogenesis of IPEX syndrome
is that, even if impairment of Treg function is the major step, other
factors such as inflammation and Th17 elevation can cooperate in
maintaining and perpetuating the immune-dysfunction.
THERAPY
Due to the limited and sporadic number of cases reported in
literature, it has been difficult up to now to compare different
therapeutic strategies and relative outcomes. Therefore, the ther-
apeutic approaches for the treatment of IPEX patients are still
based on the experiences in single patients. Moreover, given the
unclear genotype-phenotype correlation, the clinical course of the
disease and the response to therapy can be variable and not always
satisfying. Therapy is therefore targeted to the clinical manifesta-
tions and severity of the individual patient. The current treatments
available for IPEX syndrome include replacement and supportive
therapy, IS therapy, and hematopoietic stem cell transplantation
(HSCT). Nutritional support and IS therapy should be promptly
started to counteract the initial acute manifestations. A wasting
syndrome can acutely affect the outcome of these patients, calling
for a collaborative multi-disciplinary effort among clinicians from
different specialties such as gastroenterology, infectious disease,
and immunohematology.
REPLACEMENT AND SUPPORT THERAPY
At onset, the patient should be hospitalized and receive a broad-
spectrum supportive care (fluids, TPN, albumin) with replace-
ment therapy for endocrine disorders (e.g., insulin and/or thyroid
hormones), autoimmune cytopenias (e.g., hemocomponents), or
hypogammaglobulinemia (e.g., intravenous immunoglobulins).
Prophylactic antibiotics should be used considering the multi-
ple potential sources of infection such as skin lesion, damaged
gastrointestinal lining, and central venous catheter. Infectious
episodes can drastically exacerbate or complicate the existing
clinical symptoms, endangering the patient’s life.
IMMUNOSUPPRESSIVE THERAPY
Monotherapy or combination immunosuppression reported so far
has shown to be only partially effective in controlling the autoim-
mune manifestations. Multiple IS therapies are often required to
control symptoms (Gambineri et al., 2008).
Glucocorticoids (prednisone and methylprednisolone) are
used as the first line therapy to limit progression of organ dam-
age (Gambineri et al., 2008). If the response to prednisone is
inadequate, betamethasone (the equivalent oral dose) could have
significantly better efficacy (Kobayashi et al., 2001; Taddio et al.,
2007). Then other IS drugs can be added onto the steroids regimen.
Cyclosporine and/or tacrolimus have been most commonly used
in conjunction with steroids (Baud et al., 2001; Wildin et al., 2002;
Mazzolari et al., 2005; Taddio et al., 2007; Gambineri et al., 2008).
Azathioprine also has been used with steroids and/or tacrolimus
with partial control of the disease (Bindl et al., 2005). The ideal
dose of medication should be determined to maximize clinical
benefit of the individual patient while minimizing side effects.
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Thanks to a better understand the disease pathogenesis, clini-
cians nowadays tend to choose more specific IS drugs, based on
the medication’s mechanism of action. Calcineurin inhibitors have
partial efficacy with high toxicity and simultaneously suppress Teff
cells, expression of FOXP3, and Treg cell function. On the contrary,
rapamycin selectively target Teff cells and do not interfere with the
function of Treg cells, which are insensitive to mTOR inhibitors
(Battaglia et al., 2006; Allan et al., 2008). Even if it is not clear if
FOXP3mut Treg cells respond to rapamycin in the same way as
FOXP3wt, the use of rapamycin (alone or in combination with
azathioprine or steroids) has given promising clinical results in
four IPEX cases (Bindl et al., 2005; Gambineri et al., 2008; Yong
et al., 2008). In these reports, rapamycin was used not as a first line
therapy, but as a second choice when calcineurin inhibitor failed.
The dosage used (approximately 0.15 mg/kg/day) was adjusted to
maintain serum levels between 8 and 12 ng/mL. In three patients
with IPEX syndrome, the combination of rapamycin, methotrex-
ate, and steroid (in one case) and rapamycin, steroid, and azathio-
prine (in the other two) allowed to obtain clinical remission in all
cases and maintain it over time (follow-up of 5 years, 6 months,
and 1.5 years, respectively; Bindl et al., 2005). The same positive
effect was achieved in one patient with rapamycin and steroid,
and with rapamycin monotherapy in another. Both showed clin-
ical remission with a follow-up of 21 and 15 months, respectively
(Yong et al., 2008). Based on these positive responses to rapamycin,
its use as the first line IS drug in conjunction with steroid might be
considered instead of calcineurin inhibitors. Of note, administra-
tion of rapamycin should be accompanied by frequent monitoring
of serum drug level with appropriate dose adjustment, since the
enteropathy may affect the drug intestinal absorption.
In IPEX patients who survived the first years of life, immuno-
suppression may stabilize the existing symptoms, but flares of
the disease may occur and new symptoms may arise despite the
therapy.
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Currently, the only cure for IPEX syndrome is allogeneic HSCT. A
summary of the published data regarding HSCT in IPEX patients
is provided in Table 5. Early HSCT leads to the best outcome, as the
organs are yet to be damaged from autoimmunity and the adverse
effects of therapy. For this reason it is fundamental to ensure an
early diagnosis. Twenty-eight cases reported received HSCT, 6 out
of these 28 patients died despite HSCT or during conditioning
(Table 1).
Among the 15 cases of transplanted IPEX patients reported
in detail (Table 5), half of them (8/15) received the transplant
before 1 year of age, one of whom died. Among the other half,
two patients who received the transplant at 9 and 13 years of age
died of infections shortly after. More recently a 16-year-old patient
underwent HSCT and a 1-year follow-up was reported. Despite the
unfortunate outcome in some patients, the HSCT should be always
recommended as the therapy of choice.
Both myeloablative and non-myeloablative conditioning regi-
mens were used in order to limit complications associated with
transplantation. The non-myeloablative regimens may enable
reduction of both the post-transplant infectious complications
and the toxicity of high dose chemotherapy. IPEX patients are
very susceptible to the side effects of chemotherapy because of
their poor clinical conditions. The use of a non-myeloablative
conditioning can more easily result in a partial chimerism.
Both related and unrelated matched donors were used success-
fully. Only one patient received HSC from cord blood (Lucas et al.,
2007) and three from mobilized peripheral blood (Zhan et al.,
2008; Seidel et al., 2009; Burroughs et al., 2010), otherwise bone
marrow was used as source of HSC (Baud et al., 2001; Wildin et al.,
2002; Mazzolari et al., 2005; Rao et al., 2007; Dorsey et al., 2009).
The longest follow-up reported is approximately 8 years post-
HSCT for three patients, including one patient transplanted at
our Institute (unpublished observations: E. Mazzolari; M. Sei-
del; R. Bacchetta). Only one of these patients reached full-donor
chimerism, however other cases with favorable outcome despite
partial chimerism have been described. Therefore, complete donor
engraftment in all hematopoietic lineages may not be necessary,
but the preferential engraftment of donor Treg cells does indicate
that at least the replacement of this cell subset is essential to cure
the disease (Seidel et al., 2009). In light of this observation, the
choice of drugs for GvHD prophylaxis should aim for the survival
of donor Treg cells.
Since wild type Treg cells seem to be sufficient to control the
disease, future cell/gene therapy approaches designed to selectively
restore the repertoire of Treg cells represent a promising oppor-
tunity. Constitutive lenti-viral mediated overexpression of FOXP3
into CD4+ T cells can convert Teff into Treg cells both in healthy
subject (Allan et al., 2008) and in IPEX patients with different
mutations (Passerini, in preparation). When a HLA compatible
donor is not available, treatment with engineered T cells could
be envisaged. Whether these cells would survive long enough to
provide a stable life-long immune regulation without generalized
immunosuppression remains to be clarified.
CONCLUSION
Immune dysregulation, polyendocrinopathy, enteropathy, X-
linked syndrome can be suspected on the basis of clinical and
laboratory features, and the timely recognition of the disease
leads to significant therapeutic benefits. A multicentre collab-
orative effort is desirable to implement studies in a wider
cohort of patients, in order to achieve a complete knowledge
of the disease, to better understand the factors that influence
the outcome, and to identify new therapeutic targets. Func-
tional impairment of Treg cells has been recognized as the pri-
mary defect at the basis of the immunodeficiency leading to
autoimmunity in IPEX syndrome. However, there is evidence
that FOXP3 mutations can contribute to a complex immune-
dysfunction, also involving Teff cells, and possibly other cell sub-
sets. Immunological studies on IPEX syndrome have been instru-
mental in other PID to identify Treg dysfunctions, independent
from FOXP3 mutations, as cause of autoimmunity and will
most likely advance the knowledge and the therapeutic perspec-
tives of other diseases with immune dysregulation of different
origin.
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